FAQ

12 HR Treprostinil 2.5 MG Extended Release Oral Tablet

Known as: treprostinil 2.5 MG 12HR Extended Release Oral Tablet, TREPROSTINIL DIOLAMINE 2.5MG SA TAB, TREPROSTINIL DIOLAMINE 2.5MG TAB,SA [VA Product] 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2015
01220132015

Related topics

Related topics

7 relations
Decreased Blood Pressure [PE]Extended Release Oral TabletHypersensitivityProstaglandins I
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
12 HR Treprostinil 2.5 MG Extended Release Oral Tablet
Pulmonary Hypertension
Hypersensitivity
Treprostinil
Prostaglandins I
Extended Release Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Treprostinil Iontophoresis Improves Digital Blood Flow during Local Cooling in Systemic Sclerosis.
INTRODUCTION Severe Raynaud's syndrome and DUs are the most prevalent manifestations of SSc peripheral microvascular disease. We… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Review
2015
Review
2015
Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension.
Idiopathic pulmonary arterial hypertension (PAH) is a progressive disease without identifiable etiology and is characterized by… (More)
  • figure 1
  • table 1
Is this relevant?
2013
2013
Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion
INTRODUCTION Treprostinil diethanolamine is an innovative salt form of the prostacyclin analogue, treprostinil sodium, developed… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
In vitro delivery of aerosolized treprostinil via modern mechanical ventilation.
BACKGROUND The Tyvaso Inhalation System is a hand-held nebulizer system used to administer treprostinil, an approved therapy for… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?